HCW Biologics Inc (HCWB)

[Frankestin]

HCW Biologics has recently completed a $5 million follow-on offering, selling 671,140 units at $7.45 per unit, each consisting of one share and two five-year warrants. Armistice Capital appears to be the main investor, as evidenced by the progressive exercise of pre-funded warrants disclosed in late May, with 374,140 shares already issued and 139,000 still available.
Combined with the April offering, which raised about $2.5 million through the sale of shares and warrants, HCWB has now secured approximately $7.5 million in fresh capital. Add to that the recently recognized $7 million in licensing revenue from WY Biotech, and the company should now have at least $14.5 million in cash.
This strengthens their financial position not only to meet potential NASDAQ listing requirements (such as price and equity thresholds), but also to actively advance preclinical and clinical programs. Let’s not forget the previously disclosed $40 million equity line of credit — a powerful tool for the company’s financing flexibility, but potentially dilutive for existing shareholders depending on how and when it's used.
With stronger cash reserves, a focused pipeline targeting age-related diseases, and increasing chances of commercial partnerships, things might finally be heating up for HCWB, IMO.